Mainz Biomed (NASDAQ:MYNZ) Short Interest Update

Mainz Biomed (NASDAQ:MYNZ) was the target of a large drop in short interest in November. As of November 30th, there was short interest totalling 88,000 shares, a drop of 97.5% from the November 15th total of 3,570,000 shares. Based on an average daily trading volume, of 96,100 shares, the short-interest ratio is currently 0.9 days. Currently, 5.5% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright lowered Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday, November 25th.

Mainz Biomed Stock Down 12.2 %

MYNZ traded down $0.73 during trading on Wednesday, reaching $5.27. The company had a trading volume of 123,861 shares, compared to its average volume of 36,855. The business has a 50 day simple moving average of $9.82 and a 200-day simple moving average of $14.35. The stock has a market cap of $1.58 million, a P/E ratio of -0.08 and a beta of 0.06. Mainz Biomed has a 52 week low of $5.10 and a 52 week high of $53.60.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.